GSA Capital Partners LLP Takes $1.61 Million Position in Kenvue Inc. (NYSE:KVUE)

GSA Capital Partners LLP purchased a new stake in shares of Kenvue Inc. (NYSE:KVUE) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 75,175 shares of the company’s stock, valued at approximately $1,613,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Planned Solutions Inc. bought a new position in shares of Kenvue during the fourth quarter valued at $27,000. Mather Group LLC. bought a new position in shares of Kenvue during the first quarter valued at $28,000. Pacific Capital Wealth Advisors Inc. bought a new stake in Kenvue in the 4th quarter worth about $28,000. Oakworth Capital Inc. bought a new stake in Kenvue in the 1st quarter worth about $31,000. Finally, CVA Family Office LLC bought a new stake in Kenvue in the 4th quarter worth about $32,000. 97.64% of the stock is currently owned by institutional investors.

Kenvue Stock Performance

Shares of KVUE stock traded down $0.13 during trading hours on Wednesday, reaching $18.09. 3,169,522 shares of the company traded hands, compared to its average volume of 19,207,486. Kenvue Inc. has a 12-month low of $17.75 and a 12-month high of $25.61. The company has a debt-to-equity ratio of 0.66, a current ratio of 0.99 and a quick ratio of 0.68. The company has a market cap of $34.64 billion, a P/E ratio of 23.36, a P/E/G ratio of 1.93 and a beta of 1.40. The firm has a 50-day moving average price of $19.08 and a 200 day moving average price of $19.85.

Kenvue (NYSE:KVUE) last posted its quarterly earnings data on Tuesday, May 7th. The company reported $0.28 earnings per share for the quarter, beating analysts’ consensus estimates of $0.25 by $0.03. Kenvue had a return on equity of 21.06% and a net margin of 9.63%. The firm had revenue of $2.89 billion for the quarter, compared to analysts’ expectations of $3.79 billion. The firm’s revenue was down 24.9% on a year-over-year basis. As a group, sell-side analysts predict that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 22nd. Stockholders of record on Wednesday, May 8th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Tuesday, May 7th. This represents a $0.80 dividend on an annualized basis and a dividend yield of 4.42%. Kenvue’s payout ratio is currently 102.56%.

Wall Street Analyst Weigh In

Several research firms recently commented on KVUE. HSBC lifted their price objective on Kenvue from $20.00 to $21.00 and gave the stock a “hold” rating in a report on Wednesday, May 8th. William Blair began coverage on Kenvue in a report on Wednesday, April 3rd. They issued a “market perform” rating for the company. Citigroup reiterated a “neutral” rating and issued a $21.00 price objective on shares of Kenvue in a report on Tuesday, May 28th. Finally, Sanford C. Bernstein began coverage on Kenvue in a report on Thursday, April 11th. They issued an “underperform” rating and a $18.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $23.09.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.